Cellenkos®
Latest round
- Series A
Last raised
- Nov 2021
Total raised
- $15M
Investors
- 1
About Cellenkos®
Cellenkos® Inc.Cellenkos® Inc. is engaged in the development of allogeneic, tissue-targeted immune regulatory T-cell therapies. Founded by Simrit Parmar, the company is headquartered in Houston, US.Cellenkos, Inc. specializes in developing allogeneic, tissue-targeted, immune regulatory T-cell therapies, focusing on their flagship product, CK0801. This therapy aims to replace defective regulatory T cells in patients with autoimmune diseases, functioning by suppressing T cell activity to restore immune balance.Cellenkos generates revenue through partnerships with healthcare institutions and biopharmaceutical companies that utilize its therapies, particularly CK0801.
Who invested in Cellenkos®
1 investor across 1 round
See all investors in Cellenkos®
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Nov 4, 2021
Amount
$15M
Investors
Questions about Cellenkos®
Who invested in Cellenkos®?
Cellenkos® has 1 investor on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Cellenkos® raised?
Cellenkos® has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Cellenkos® last raise money?
Cellenkos®'s most recent round on record is a Series A, in Nov 2021.
What does Cellenkos® do?
Cellenkos® is a biotechnology company.
Where is Cellenkos® headquartered?
Cellenkos® is headquartered in Houston, US.
Which VCs invest in companies like Cellenkos®?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Cellenkos®'s stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Cellenkos®? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.